Literature DB >> 31014144

Brentuximab vedotin as a bridge to allogeneic stem-cell transplantation for refractory or relapsing patients with CD30 positive anaplastic or T-cell non-Hodgkin lymphomas: a study on behalf of the SFGM-TC.

Sylvain Garciaz1, Mickael Loschi2, Adèle De Masson3, Lucie Biard4, Mélanie Mercier5, Cécile Tomowiak6, Jeremy Delage7, Hélène Labussiere-Wallet8, David Sibon9, Ophélie Cassuto2, Cécile Borel10, Jérome Cornillon11, Stanislas Nimubona12, Amandine Charbonnier13, Pauline Brice14, Gérard Socié14, Reda Bouabdallah1, Régis Peffault de Latour15, Flore Sicre de Fontbrune15.   

Abstract

Entities:  

Year:  2019        PMID： 31014144     DOI： 10.1080/10428194.2019.1599112

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  1 in total

1.  Case Report: Graft Versus Tumor Effect After Non-Myeloablative Allogeneic Stem-Cell Transplantation in a Patient With Brentuximab-Vedotin Refractory Sezary Syndrome.

Authors:  Georg-Nikolaus Franke; Konstantin Dumann; Madlen Jentzsch; Astrid Monecke; Christine Doehring; Claudia Nehring-Vucinic; Sebastian Schwind; Dietger Niederwieser; Uwe Platzbecker; Mirjana Ziemer; Vladan Vucinic
Journal:  Front Oncol       Date:  2021-12-09       Impact factor: 6.244
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.